Provided by Tiger Trade Technology Pte. Ltd.

GRAIL, Inc.

53.23
-4.8700-8.38%
Post-market: 53.250.0200+0.04%19:47 EST
Volume:1.95M
Turnover:105.20M
Market Cap:2.15B
PE:-4.79
High:56.87
Open:56.00
Low:52.56
Close:58.10
52wk High:118.84
52wk Low:20.44
Shares:40.33M
Float Shares:34.19M
Volume Ratio:0.35
T/O Rate:5.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.1105
EPS(LYR):-11.1105
ROE:-16.07%
ROA:-11.31%
PB:0.83
PE(LYR):-4.79

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Deckers Outdoor, CDT Equity, Comfort Systems

Reuters
·
Feb 20

U.S. Stock Futures Edge Lower Ahead of Key Economic Data and Supreme Court Ruling

Deep News
·
Feb 20

Top Premarket Decliners

MT Newswires Live
·
Feb 20

BUZZ-U.S. STOCKS ON THE MOVE-Akamai, Grail, Candel Therapeutics

Reuters
·
Feb 20

Grail Shares Down 48.5% Premarket After Q4 Results, Cancer Test Misses Main Study Goal

THOMSON REUTERS
·
Feb 20

U.S. Stocks to Watch: Opendoor, Nvidia, Grail, Newmont, AppLovin, Akamai, and More

Dow Jones
·
Feb 20

These Stocks Are Today's Movers: Opendoor, Nvidia, Grail, Newmont, AppLovin, and More -- Barrons.com

Dow Jones
·
Feb 20

Stock Track | GRAIL, Inc. Plunges 47.50% in Pre-Market as Cancer Test Trial Misses Primary Endpoint

Stock Track
·
Feb 20

Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame. -- Barrons.com

Dow Jones
·
Feb 20

Premarket Movers | Opendoor Surges 15%; AppLovin Jumps 5%; Copart Drops 7%; Akamai Sinks 9%; Grail Tumbles 47%

Tiger Newspress
·
Feb 20

Grail Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Feb 20

24H|Opendoor up 15%; Applovin up 6%; GRAIL down 46%; Copart down 7%

Tiger Newspress
·
Feb 20

Stock Track | GRAIL, Inc. Plunges 47.49% in Post-Market as Key Cancer Test Trial Misses Primary Endpoint

Stock Track
·
Feb 20

Stocks to Watch: Akamai Technologies, Copart, Grail

Dow Jones
·
Feb 20

Earnings Flash (GRAL) GRAIL Posts Q4 Loss $2.44 per Share, vs. FactSet Est of Loss of $2.70

MT Newswires Live
·
Feb 20

BUZZ-Grail slumps after Q4 results, cancer test misses main study goal

Reuters
·
Feb 20

BRIEF-Grail Says Primary Endpoint Of Statistically Significant Combined Stage III-IV Reduction Was Not Met

Reuters
·
Feb 20

Stock Track | GRAIL, Inc. Plunges 30.09% After-Hours as Key Trial Endpoint Misses Target

Stock Track
·
Feb 20

GRAIL FY 2025 net loss was USD 408.4 million, improving 80%

Reuters
·
Feb 20

GRAIL Q4 EPS $(2.44) Beats $(2.73) Estimate, Sales $43.597M Miss $43.600M Estimate

Benzinga
·
Feb 20